| GlaxoSmithKline Makes Aggressive Play for Emerging Markets ChinaBio Today submits: Because GlaxoSmithKline (GSK) wants to double its China and India revenues by 2015, the company will significantly reduce its prices – as much as 70% – to raise revenues. The company readily admits it is trailing its multinational rivals such as Pfizer (PFE) and Sanofi-Aventis (SNY) in developing markets.Abbas Hussain, President of Emerging Markets for Glaxo, said in an interview with Bloomberg News:Complete Story » seekingalpha.com |
Scrutiny Turns to Retirement Centers A fast-growing sector of senior housing is coming under increased scrutiny in Washington—continuing-care retirement communities. online.wsj.com |
ZymoGenetics Inc Q2 2010 Earnings Call Transcript ZymoGenetics Inc (ZGEN)Q2 2010 Earnings CallAugust 03, 2010 4:30 p.m. ETComplete Story » seekingalpha.com |
Enzo Biochem Initiates Clinical Trial for Treatment of Uveitis at NIH [Business Wire] - Enzo Biochem, Inc. , announced today that, following filing of a investigational new drug application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company’s proprietary oral therapeutic for chronic non-infectious uveitis. us.rd.yahoo.com |
Kendall Law Group Investigates Clarient, Inc. Acquisition for Shareholders [Business Wire] - Kendall Law Group, led by former federal judge Joe Kendall, is investigating Clarient, Inc. for shareholders in connection with the proposed acquisition of the company by GE Healthcare. us.rd.yahoo.com |